1. Abiraterone acetate versus nonsteroidal antiandrogen with androgen deprivation therapy for high‐risk metastatic hormone‐sensitive prostate cancer. Issue 1 (24th September 2021) Authors: Yanagisawa, Takafumi; Kimura, Takahiro; Mori, Keiichiro; Suzuki, Hirotaka; Sano, Takayuki; Otsuka, Takashi; Iwamoto, Yuya; Fukuokaya, Wataru; Miyajima, Keiichiro; Enei, Yuki; Sakanaka, Keigo; Matsukawa, Akihiro; Onuma, Hajime; Obayashi, Koki; Tsuzuki, Shunsuke; Hata, Kenichi; Shimomura, Tatsuya; ... Journal: Prostate Issue: Volume 82:Issue 1(2022) Page Start: 3 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Docetaxel versus abiraterone for metastatic hormone‐sensitive prostate cancer with focus on efficacy of sequential therapy. Issue 6 (20th January 2023) Authors: Yanagisawa, Takafumi; Hata, Kenichi; Narita, Shintaro; Hatakeyama, Shingo; Mori, Keiichiro; Yata, Yuji; Sano, Takayuki; Otsuka, Takashi; Hara, Shuhei; Miyajima, Keiichiro; Enei, Yuki; Fukuokaya, Wataru; Nakazono, Minoru; Matsukawa, Akihiro; Miki, Jun; Habuchi, Tomonori; Ohyama, Chikara; Shariat, ... Journal: Prostate Issue: Volume 83:Issue 6(2023) Page Start: 563 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗